BAIYUNSHAN PH (00874) announced that its subsidiary Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. ("Baiyunshan Hanfang") has recently received the Marketing Authorization Approval Notice for Structured Triglycerides Chemical Raw Material issued by the National Medical Products Administration.

According to the company, structured triglycerides serve as a key raw material for preparations including Structured Fat Emulsion Injection (C6-24) and Structured Fat Emulsion (20%)/Amino Acid (16)/Glucose (13%) Injection. These products are indicated for parenteral nutrition fat supplementation in patients who are unable to receive, have insufficient, or are contraindicated for oral or enteral nutrition intake.

The receipt of the Marketing Authorization Approval Notice for Structured Triglycerides by Baiyunshan Hanfang indicates that this raw material drug meets the relevant national pharmaceutical evaluation technical standards and can be produced and marketed. This approval will help enrich Baiyunshan Hanfang's pharmaceutical lipid raw material and excipient product portfolio, further enhancing the company's market competitiveness in lipid raw material and excipient products.

The company noted that receiving this Marketing Authorization Approval Notice will not have a significant impact on current period performance.